The FDA-Approved Oral Drug Nitazoxanide Amplifies Host Antiviral Responses and Inhibits Ebola Virus

• Published in: iScience Vol. 19; pp. 1279 - 1290
• Main Authors: Jasenosky, Luke D., Cadena, Cristhian, Mire, Chad E., Borisevich, Viktoriya, Haridas, Viraga, Ranjbar, Shahin, Nambu, Aya, Bavari, Sina, Soloveva, Veronica, Sadukhan, Supriya, Cassell, Gail H., Geisbert, Thomas W., Hur, Sun, Goldfeld, Anne E.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 27.09.2019; Elsevier
• Subjects: Immune Response; Mechanism of Action; Pathogenic Organism; Viral Microbiology; Mechanism of Action; Pathogenic Organism; Viral Microbiology; Immune Response

Here, we show that the US Food and Drug Administration-approved oral drug nitazoxanide (NTZ) broadly amplifies the host innate immune response to viruses and inhibits Ebola virus (EBOV) replication. We find that NTZ enhances retinoic-acid-inducible protein I (RIG-I)-like-receptor, mitochondrial anti...